Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, July 22 at 2:00 PM EDT

Register Free →
← Back to NAICS Codes
NAICS Code· 541714

Research and Development in Biotechnology (except Nanobiotechnology)

This U.S. industry comprises establishments primarily engaged in conducting biotechnology (except nanobiotechnology) research and experimental development. Biotechnology (except nanobiotechnology) research and experimental development involves the study of the use of microorganisms and cellular and biomolecular processes to develop or alter living or non-living materials. This research and development in biotechnology (except nanobiotechnology) may result in development of new biotechnology (except nanobiotechnology) processes or in prototypes of new or genetically-altered products that may be reproduced, utilized, or implemented by various industries. Illustrative Examples: Cloning research and experimental development laboratories DNA technologies (e.g., microarrays) research and experimental development laboratories Nucleic acid chemistry research and experimental development laboratories Protein engineering research and experimental development laboratories Recombinant DNA research and experimental development laboratories Cross-References. Establishments primarily engaged in--Show more

NAICS 541714 – Research and Development in Biotechnology (except Nanobiotechnology) encompasses scientific research and development activities focused on applying biological systems, organisms, or cellular processes to develop novel therapeutics, diagnostics, vaccines, and biomanufacturing platforms. This sector supports federal initiatives in precision medicine, infectious disease mitigation, biosecurity, and advanced bioprocessing, often involving recombinant DNA technology, protein engineering, cell line development, and high-throughput screening.

70
Active Contracts
$1.1B
Total Obligations (12mo)
365
Awarded Contracts (12mo)
289
Contractors Awarded (12mo)
-86.6%
YoY Growth

Contract Opportunities

Active solicitations and awarded contracts classified under NAICS 541714Research and Development in Biotechnology (except Nanobiotechnology).

Dotted
NAICS 541714 FAQ

Frequently Asked Questions

NAICS code 541714 covers Research and Development in Biotechnology (except Nanobiotechnology). This U.S. industry comprises establishments primarily engaged in conducting biotechnology (except nanobiotechnology) research and experimental development. Biotechnology (except nanobiotechnology) research and experimental development involves the study of the use of microorganisms and cellular and biomolecular processes to develop or alter living or non-living materials. This research and development in biotechnology (except nanobiotechnology) may result in development of new biotechnology (except nanobiotechnology) processes or in prototypes of new or genetically-altered products that may be reproduced, utilized, or implemented by various industries. Illustrative Examples: Cloning research and experimental development laboratories DNA technologies (e.g., microarrays) research and experimental development laboratories Nucleic acid chemistry research and experimental development laboratories Protein engineering research and experimental development laboratories Recombinant DNA research and experimental development laboratories Cross-References. Establishments primarily engaged in--

Recently Posted in Research and Development in Biotechnology (except Nanobiotechnology)

NAICS: 541714
New
Federal
TECHNOLOGY LICENSING OPPORTUNITY: Platform to Accelerate Discovery of Tailored Industrial Enzymes (PAD-TIE)The PAD-TIE platform, developed by NREL and Los Alamos National Laboratory, is a high-throughput screening system designed to rapidly identify and optimize enzymes capable of breaking down polyethylene terephthalate (PET) plastic under industrially relevant conditions. Unlike traditional methods that test enzymes one at a time, PAD-TIE evaluates tens of thousands of enzyme variants simultaneously, measuring their activity, stability, and production efficiency in a single process, eliminating costly purification steps and reducing time-to-identification. The system operates at the optimal temperature for PET degradation and is validated in lab-scale bioreactors that mimic real-world recycling environments, enabling the conversion of plastic waste into reusable monomers without harsh chemicals or excessive energy use. With a Technology Readiness Level of 6, the platform is a fully functional prototype with all components tested, and three U.S. patents are pending, making it a mature and protected innovation ready for commercial adoption. PAD-TIE is positioned to serve a broad range of industries including plastic recycling, waste management, polymer manufacturing, and sustainable materials development. Its adaptability allows customization for different PET compositions, additives, and processing conditions, ensuring compatibility with existing infrastructure. The platform’s efficiency and scalability offer a cost-effective solution for scaling enzymatic plastic degradation at an industrial level. Los Alamos National Laboratory is seeking industry partners through exclusive or non-exclusive licensing agreements to further develop and deploy the technology, with applications spanning bioremediation, bioplastics, and closed-loop recycling systems. Interested parties must respond by October 1, 2026, and inquiries should be directed to the provided licensing contacts. The technology is available for commercialization under a non-set-aside procurement with a NAICS code of 541714, and performance will occur in Los Alamos, New Mexico.
Triad - DOE Contractor

POSTED

4 days ago

DEADLINE

in 3 months
View Details
NAICS: 541714
New
Federal
RFP - 2-PAM Autoinjectors for Project Bioshield (PBS)The Biomedical Advanced Research and Development Authority (BARDA) is seeking proposals under solicitation 75A50126R00002 to develop, obtain regulatory approval for, and procure approximately two million 2-PAM (600mg) autoinjectors as a drug/device combination product for the treatment of organophosphate poisoning, including nerve agents, in both adult and pediatric populations. This effort supports the Strategic National Stockpile (SNS) and CHEMPACK Program. The contract is structured as a hybrid cost-plus-fixed-fee and firm-fixed-price instrument with an anticipated base performance period of up to 36 months and potential extension through options to a total duration of eight years. Key deliverables include late-stage clinical development, regulatory submission and approval, and large-scale manufacturing of autoinjectors, with production split across multiple CLINs totaling 2 million units. The solicitation is issued as a Statement of Objectives, requiring offerors to submit a comprehensive Statement of Work and Risk Mitigation Plan addressing program management, product development, supply chain logistics, and optional post-marketing commitments. Manufacturing and packaging must adhere to Good Manufacturing Practice regulations under 21 CFR Part 820, and all products must maintain strict temperature controls during transit, with ambient exposure logging required from the offeror’s validated facility until acceptance by the government at the ASPR/SNS location in Washington, D.C. All proposals must comply with mandatory eligibility criteria, including adherence to FAR and HHSAR clauses covering cost allowability, inspection, intellectual property, anti-kickback, and contingency fee restrictions. Offerors are required to complete SAM.gov representations and certifications, submit a detailed organizational chart identifying key personnel including a Program Director, Chief Scientific/Medical Officer, Manufacturing Lead, Regulatory Affairs Lead, and Project Manager, and demonstrate compliance with human subject protections under 45 CFR 46. Security requirements mandate layered physical controls, identification verification for personnel and visitors, and robust information and cyber security protocols encompassing access controls, intrusion detection, and encryption. Proposals must be submitted by July 30, 2026, and remain firm for 120 days. Evaluation will prioritize technical merit, past performance, and overall value over cost, with non-cost factors carrying significantly greater weight. Contract administration requires electronic invoice submissions via the Treasury IPP system to designated federal offices and strict adherence to documentation handling, packaging, and delivery protocols. The procurement is open to all qualified entities without set-aside restrictions
Barda - Aspr / Daappo / Barda Dcma

POSTED

4 days ago

DEADLINE

in 18 days
View Details
NAICS: 541714
New
Grant
Renewable Energy and Solar Grid Integration R&DThe contract titled Renewable Energy and Solar Grid Integration R&D is a subcontract aimed at advancing solar energy systems, battery storage, and smart grid integration specifically designed for arid climates through joint research efforts involving U.S., Israeli, and MENA region partners. The initiative focuses on developing technologies that enhance energy resilience, efficiency, and reliability in hot, dry environments where traditional energy infrastructure faces unique challenges. Collaborative innovation is central to the project, with an explicit goal of moving researched solutions toward commercial viability, ensuring practical deployment and market adoption in regions with high solar potential but limited water and grid stability resources. Research activities under this contract must be completed and tested by the response deadline of September 30, 2026, following a July 6, 2026 posting date. The work is classified under the NAICS code 541714, indicating it falls within research and development in the physical, engineering, and life sciences. Administration is handled by the Department of State’s Assistance Coordination office, though no specific location for performance or contact details are provided. The subcontract seeks to leverage international expertise to create scalable, localized energy solutions, with an emphasis on cross-border cooperation and technology transfer to support sustainable development and energy security in arid zones.
Assistance Coordination

POSTED

7 days ago

DEADLINE

in 3 months
View Details
NAICS: 541714
Federal
Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) - TA3The RAPIID program, specifically Task Area 3, aims to bridge the gap between lab-scale breakthroughs in shelf-stable blood analogs and real-world deployment by advancing the regulatory approval, manufacturing scalability, and field usability of components originally developed under the FSHARP program. These components, designed to replicate the critical functions of whole blood—oxygen delivery, hemostasis, and volume expansion—now require rigorous clinical validation to demonstrate safety and efficacy when used in combination, as well as scalable production processes to ensure consistent, high-volume output. Efforts under this solicitation will focus on pushing these technologies through the regulatory pathway to secure necessary approvals for military and civilian use in austere, pre-hospital environments. The initiative seeks to develop and scale enabling fielding technologies that support the deployment, storage, and administration of these blood analogs outside controlled laboratory settings. This includes not only the components themselves but also the logistical and operational frameworks needed to integrate them into frontline medical workflows. Proposals must address the full spectrum of challenges—from manufacturing robustness and regulatory compliance to usability in extreme conditions—while aligning with the program’s goal of delivering a complete, authorized system capable of saving lives where traditional blood supplies are unavailable. The solicitation, issued by DARPA’s Biological Technologies Office, has a response deadline of July 29, 2026, and is open to all qualified entities, targeting the NAICS code 541714 for research and development in physical, engineering, and life sciences.
Defense Advanced Research Projects Agcy

POSTED

10 days ago

DEADLINE

in 17 days
View Details

Win Contracts in Research and Development in Biotechnology (except Nanobiotechnology)

Get AI-powered intelligence on NAICS 541714 procurement

Real-time contract opportunities for NAICS 541714 (Research and Development in Biotechnology (except Nanobiotechnology))

AI-powered matching based on your business capabilities and past performance

Competitive analysis of contractors winning awards in this industry

Automated alerts when new opportunities are posted

Miguel
Hillary
Keith Deutsch
Christine

Join 500+ contractors already using CLEATUS